skip to primary navigationskip to content

07.10.15 Nobel Prize for Chemistry recognises discovery of DNA repair mechanisms

last modified Oct 09, 2015 09:01 AM
Chemistry Nobel Prize for groundbreaking research in field of DNA repair is basis for Gurdon Institute therapeutic success
07.10.15 Nobel Prize for Chemistry recognises discovery of DNA repair mechanisms

3-D structure of PARP1 protein. Credit Wikimedia Commons via CC-BY-SA 3.0

The three award winners, Tomas Lindahl, Paul Modrich and Aziz Sancar, made their discoveries on the enzymatic mechanisms of DNA repair several decades ago. That work laid the ground for other researchers to investigate the role of DNA repair in disease.

Certain cancers triggered by faulty BRCA1 or BRCA2 genes have problems in one of their DNA repair pathways. The Gurdon Institute's Steve Jackson set out to exploit the genetic vulnerability of such cells by developing drugs to block another DNA repair pathway that is controlled by an enzyme called PARP. Through establishing the Gurdon Institute spin-out company, KuDOS Pharmaceuticals, Steve's initiative led to the development of the clinically successful, orally administered PARP inhibitor olaparib (Lynparza), which kills cancer cells with faulty BRCA1/2 genes but not healthy cells of cancer patients that still have a working DNA repair mechanism.

As the Nobel Foundation's own background document on DNA repair says: 

"In fact, in many forms of cancer, one or more of these repair systems have been entirely or partially switched off...these sick cells are even more dependent on the repair systems that are still functioning; without these, their DNA will become too damaged and the cells will die. Researchers are attempting to utilise this weakness in the development of new cancer drugs...One example of a pharmaceutical that inhibits a repair system in cancer cells is olaparib."

Lynparza structure

Lynparza has been licensed for use in Europe and the USA against certain ovarian cancers, and clinical trials are still in progress in a number of other types of cancer.

Studying development to understand disease

The Gurdon Institute is funded by Wellcome and Cancer Research UK to study the biology of development, and how normal growth and maintenance go wrong in cancer and other diseases.

combinedLogo x3 trans2018


Share this

Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48

The developmental origin of brain tumours: a cellular and molecular framework

Bioinformatics challenges and perspectives when studying the effect of epigenetic modifications on alternative splicing

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity

Combinational Treatment of Trichostatin A and Vitamin C Improves the Efficiency of Cloning Mice by Somatic Cell Nuclear Transfer

Predominant Asymmetrical Stem Cell Fate Outcome Limits the Rate of Niche Succession in Human Colonic Crypts

G9a regulates temporal preimplantation developmental program and lineage segregation in blastocyst

Validating the concept of mutational signatures with isogenic cell models

A PAX5-OCT4-PRDM1 developmental switch specifies human primordial germ cells

Targeting NAT10 enhances healthspan and lifespan in a mouse model of human accelerated aging syndrome

An alternative mode of epithelial polarity in the Drosophila midgut

Detection of functional protein domains by unbiased genome-wide forward genetic screening

Fank1 and Jazf1 promote multiciliated cell differentiation in the mouse airway epithelium

Genome organization at different scales: nature, formation and function

Mouse Model of Alagille Syndrome and Mechanisms of Jagged1 Missense Mutations


Link to full list on PubMed